Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
Management
Medical & Scientific Advisory Board
Partners
Distributors
Compliance
Careers
Technology
Our Science
NETs Platform
SubB2M Platform
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Resources
Business Development
Products
Our Products
EXO-NET® Pan-Exosome
Product Overview
Technical Information
Data & Figures
Ordering
hTERT ICC Test
Pipeline
Development Pipeline
NeuCA15-3 Test
NeuCA125 Test
EXO-Ovarian Cancer Test
Exosome Therapeutics
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
News & Events
INOVIQ in the News
Conferences & Events
Contact
Contact Us
Subscribe to Email Alerts
ASX Announcements
Heading &
Sub-heading can be edited through HQI
Investors
>
ASX Announcements
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
13-Apr-2021
BARD1 Signs Option Agreement for Type 3C Diabetes Test
19-Mar-2021
Appendix 2A
16-Mar-2021
Positive Results Evaluation of EXO-NET in Pancreatic Cancer
15-Mar-2021
Appendix 2A
15-Mar-2021
Australian Patent Granted for hTERT
12-Mar-2021
BARD1 Achieves hTERT Registration and First Order in Korea
2-Mar-2021
Appendix 2A
1-Mar-2021
Change in substantial holding
1-Mar-2021
Ceasing to be a substantial holder
26-Feb-2021
Appendix 4D and Half-year financial report
Previous
1
2
3
4
5
6
7
8
9
Next
